Abstract
An isolated rat muscle preparation was developed to screen for muscle damage (myotoxic potential) following intramuscular injections. Myotoxicity is evaluated by the total cumulative efflux of the enzyme creatine kinase from the extensor digitorum longus muscle into the incubation medium over a 2-hr period or by the slope of the cumulative creatine kinase efflux curve. The system allows for rapid screening of compounds and/or formulations regarding their myotoxic potential and is not sensitive to fluctuations of in vivo creatine kinase levels caused by animal handling or patient conditions. A good rank-order correlation was obtained between this in vitro technique and the in vivo myotoxicity of a number of pharmaceutical formulations, as indicated by circulating creatine kinase levels and histological observations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
D. J. Greenblatt and M. D. Allen. JAMA 240:542–544 (1978).
P. R. Alper. Arch. Intern. Med. 138:1705–1710 (1978).
U.S. Department of Health, Education, and Welfare. National Ambulatory Medical Care Survey—1975, National Center for Health Statistics, Rockville, Md. (1977).
R. Bais and J. B. Edwards. CRC Crit. Rev. Clin. Lab. Sci. 16:291–335 (1982).
L. Cacace. N. Engl. J. Med. 287:309–310 (1972).
K. E. Andersen and T. Damsgaard. Acta Med. Scand. 199:317–319 (1976).
A. K. Knirsch and E. J. Gralla. N. Engl. J. Med. 282:1081–1082 (1970).
J. C. Zener and D. C. Harrison. Arch. Intern. Med. 134:48–49 (1974).
H. Y. Meltzer, S. Mrozak, and M. Boyer. Am. J. Med. Sci. 259:42–48 (1970).
K. Korttila, A. Sothman, and P. Andersson. Acta Pharmacol. Toxicol. 39:104–117 (1976).
D. G. Warnock and G. L. Ellman. Science 164:276 (1969).
A. M. Attar and C. Mata. Med. Ann. D.C. 40:92–93 (1971).
V. Diness. Acta Pharmacol. Toxicol. 56:410–415 (1985).
E. Steiness, O. Svendsen, and F. Rasmussen. Clin. Pharm. Ther. 16:430–434 (1974).
E. Steiness, F. Rasmussen, O. Svendsen, and P. Nielsen. Acta Pharmacol. Toxicol. 42:357–364 (1978).
O. Svendsen, F. Rasmussen, P. Nielsen, and E. Steiness. Acta Pharmacol. Toxicol. 44:324–328 (1979).
C. Surber and H. Sucker. Pharm. Res. 4:490–494 (1987).
O. Svendsen, F. Hojelse, and R. E. Bagdon. Acta Pharmacol. Toxicol. 56:183–190 (1985).
P. D. Williams, B. G. Masters, L. D. Evans, D. A. Laska, and G. H. Hottendorf. Fund. Appl. Toxicol. 9:10–17 (1987).
S. Oshida, K. Degawa, Y. Takahasi, and S. Akaishi. Tohoku J. Exp. Med. 127:301–316 (1979).
J. E. Gray, R. N. Weaver, J. Moran, and E. S. Feenstra. Toxicol. Appl. Pharm. 27:308–321 (1974).
F. R. Sidell, D. L. Culver, and A. Kaminskis. JAMA 229:1894–1897 (1974).
H. Hsu and J. Wantanabe. Chem. Pharm. Bull. 31:626–631 (1983).
K. W. Reed and S. H. Yalkowsky. J. Parent. Sci. Tech. 39:64–68 (1985).
R. Dempsey, J. Morgan, and L. Cohen. Clin. Pharm. Ther. 18:104–111 (1975).
K. E. Avis. In A. F. Gennaro (ed.), Remington's Pharmaceutical Sciences, 17th ed., Mack, Easton, Pa., 1985, p. 1522.
G. E. Paget and H. McG. Scott. Br. J. Pharmacol. 12:427–433 (1957).
H. O. Gloor, C. Vorburger, and J. Schadelin. Schweiz. Med. Wschr. 107:948–952 (1977).
D. J. Greenblatt, D. W. Duhme, and J. Koch-Weser. N. Engl. J. Med. 288:689 (1973).
I. Kronborg, D. Hunt, and A. J. Goble. Med. J. Aust. 1:635 (1975).
A. J. Wilensky and J. A. Lowden. Neurology 23:318–324 (1973).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brazeau, G.A., Fung, HL. An In Vitro Model to Evaluate Muscle Damage Following Intramuscular Injections. Pharm Res 6, 167–170 (1989). https://doi.org/10.1023/A:1015940811827
Issue Date:
DOI: https://doi.org/10.1023/A:1015940811827